ReviewCold Spring Harbor perspectives in medicine2014
Novel vaccination strategies against tuberculosis.
Review in Cold Spring Harbor perspectives in medicine, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 80 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
80 citing papers in PubMed, 153 citations in OpenAlex.
- Antigen 85B ofVaccines · 2026Review
- Applications of humanized mice inMolecular medicine reports · 2026Review
- Construction and characterization of novelInfection and immunity · 2026Article
- Article
- Novel fusion protein REA induces robust prime protection against tuberculosis in mice.NPJ vaccines · 2025Article
- Field Trial with Vaccine Candidates Against Bovine Tuberculosis Among Likely Infected Cattle in a Natural Transmission Setting.Vaccines · 2024Article
- Review
- Live Attenuated Vaccines against Tuberculosis: Targeting the Disruption of Genes Encoding the Secretory Proteins of Mycobacteria.Vaccines · 2024Review
- BCG-booster vaccination with HSP90-ESAT-6-HspX-RipA multivalent subunit vaccine confers durable protection against hypervirulent Mtb in mice.NPJ vaccines · 2024Article
- The combination ofFrontiers in immunology · 2024Article
- Enhancing cell-mediated immunity through dendritic cell activation: the role of Tri-GalNAc-modified PLGA-PEG nanoparticles encapsulating SR717.Frontiers in immunology · 2024Article
- DNA and RNA vaccines against tuberculosis: a scoping review of human and animal studies.Frontiers in immunology · 2024Article
- Enhancement of the immunogenicity of aIranian journal of basic medical sciences · 2024Article
- Safety and Immunogenicity of RecombinantInternational journal of molecular sciences · 2023Article
- Recombinant Pichinde viral vector expressing tuberculosis antigens elicits strong T cell responses and protection in mice.Frontiers in immunology · 2023Article
- Interleukin-27 impairs BCG antigen clearance and T cell stimulatory potential by neonatal dendritic cells.Current research in microbial sciences · 2023Article
- A novel multistage antigens ERA005f confer protection againstFrontiers in immunology · 2023Article
- Article
- BCG Vaccine-The Road Not Taken.Microorganisms · 2022Review
- Impact ofCells · 2022Article
20 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The tuberculosis (TB) pandemic continues to rampage despite widespread use of the BCG (Bacillus Calmette-Guérin) vaccine. Novel vaccination strategies are urgently needed to arrest global transmission and prevent the uncontrolled development of multidrug-resistant forms of Mycobacterium tuberculosis. Over the last two decades, considerable progress has been made in the field of vaccine development with numerous innovative preclinical candidates and more than a dozen vaccines in clinical trials. These vaccines are developed either as boosters of the current BCG vaccine or as novel prime vaccines to replace BCG. Given the enormous prevalence of latent TB infection, vaccines that are protective on top of an already established infection remain a high priority and a significant scientific challenge. Here we discuss the current state of TB vaccine research and development, our understanding of the underlying immunology, and the requirements for an efficient TB vaccine.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.